ASTEX PHARMACEUTICALS, INC.
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Established
- 2011-01-01
- Employees
- 136
- Market Cap
- -
- Website
- http://www.astx.com
Decitabine Versus Supportive Care in Adults With Advanced-stage MDS
- Conditions
- First Posted Date
- 2002-08-12
- Last Posted Date
- 2024-08-02
- Lead Sponsor
- Astex Pharmaceuticals, Inc.
- Target Recruit Count
- 160
- Registration Number
- NCT00043381
- Locations
- 🇺🇸
University of Illinois at Chicago, Chicago, Illinois, United States
🇺🇸Alta Bates Comprehensive Cancer Center, Berkeley, California, United States
🇺🇸Scripps Clinic, Escondido, California, United States
Phase II Trial of Decitabine in Patients With Chronic Myelogenous Leukemia Blast Phase Who Are Refractory to Imatinib Mesylate (Gleevec)
- Conditions
- First Posted Date
- 2002-07-23
- Last Posted Date
- 2024-08-02
- Lead Sponsor
- Astex Pharmaceuticals, Inc.
- Target Recruit Count
- 40
- Registration Number
- NCT00042003
- Locations
- 🇺🇸
City of Hope Medical Center, Duarte, California, United States
🇺🇸USC/Norris Cancer Center, Los Angeles, California, United States
🇺🇸Metro-Minnesota CCOP, Saint Louis Park, Minnesota, United States
Phase II Trial of Decitabine in Patients With Chronic Myelogenous Leukemia Chronic Phase Who Are Refractory to Imatinib Mesylate (Gleevec)
- Conditions
- First Posted Date
- 2002-07-23
- Last Posted Date
- 2009-10-14
- Lead Sponsor
- Astex Pharmaceuticals, Inc.
- Target Recruit Count
- 40
- Registration Number
- NCT00042016
- Locations
- 🇺🇸
Scripps Clinic, Escondido, California, United States
🇺🇸Metro-Minnesota CCOP, St. Louis Park, Minnesota, United States
🇺🇸City of Hope Medical Center, Duarte, California, United States
Phase II Trial of Decitabine in Patients With Chronic Myelogenous Leukemia Accelerated Phase Who Are Refractory to Imatinib Mesylate (Gleevec)
- Conditions
- First Posted Date
- 2002-07-23
- Last Posted Date
- 2007-12-17
- Lead Sponsor
- Astex Pharmaceuticals, Inc.
- Target Recruit Count
- 40
- Registration Number
- NCT00041990
- Locations
- 🇺🇸
Metro-Minnesota CCOP, St. Louis Park, Minnesota, United States
🇨🇦Princess Margaret Hospital, Toronto, Ontario, Canada
🇺🇸New York Medical College, Valhalla, New York, United States
Dose-finding Study Using Pentostatin for Injection in the Treatment of Steroid-refractory aGvHD
- Conditions
- First Posted Date
- 2002-04-04
- Last Posted Date
- 2024-08-02
- Lead Sponsor
- Astex Pharmaceuticals, Inc.
- Target Recruit Count
- 36
- Registration Number
- NCT00032773
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States